Recovering the Broken-Hearted

Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions

Despite improvements in outcomes in the last few decades for heart failure (HF) with reduced ejection fraction (HFrEF), there still remains a need for novel therapies as many patients incompletely recover with existing therapies and progress to advanced HF. In this review, we will discuss recent advances in the management of HFrEF with a focus on upcoming therapies that hold the greatest promise for clinical use. We will discuss novel pharmacological therapies and areas of uncertainty with existing therapies. We will also discuss the potential utility and controversy surrounding novel interventions for HF such as percutaneous mitral valve repair, atrial fibrillation ablation, and other emerging interventions with positive signals for benefit in HFrEF. Finally, we will summarize the current state of stem cell and gene therapy for HFrEF and future directions.

Collapse

Challenges and Future Directions in Left Ventricular Assist Device Therapy

The clinical use of left ventricular assist devices (LVADs) in the growing epidemic of heart failure has improved quality of life and long-term survival for this otherwise devastating disease. The current generation of commercially available devices offers a smaller profile that simplifies surgical implantation, a design that optimizes blood flow characteristics, with less adverse events and improved durability than their predecessors. Despite this, the risk for adverse events remains significant, as do burdens for patients and their caregivers. Appropriate patient selection remains key to optimal LVAD outcomes.

Normal fluid stresses are prevalent in rotary ventricular assist devices: A computational fluid dynamics analysis

Despite the evolution of ventricular assist devices, ventricular assist device patients still suffer from complications due to the damage to blood by fluid dynamic stress. Since rotary ventricular assist devices are assumed to exert mainly shear stress, studies of blood damage are based on shear flow experiments. However, measurements and simulations of cell and protein deformation show normal and shear stresses deform, and potentially damage, cells and proteins differently. The aim was to use computational fluid dynamics to assess the prevalence of normal stress, in comparison with shear stress, in rotary ventricular assist devices. Our calculations showed normal stresses do occur in rotary ventricular assist devices: the fluid volumes experiencing normal stress above 10 Pa were 0.011 mL (0.092%) and 0.027 mL (0.39%) for the HeartWare HVAD and HeartMate II (HMII), and normal stresses over 100 Pa were present. However, the shear stress volumes were up to two orders of magnitude larger than the normal stress volumes. Considering thresholds for red blood cell and von Willebrand factor deformation by normal and shear stresses, the fluid volumes causing deformation by normal stress were between 2.5 and 5 times the size of those causing deformation by shear stress. The exposure times to the individual normal stress deformation regions were around 1 ms. The results clearly show, for the first time, that while blood within rotary ventricular assist devices experiences more shear stress at much higher magnitudes as compared with normal stress, there is sufficient normal stress exposure present to cause deformation of, and potentially damage to, the blood components. This study is the first to quantify the fluid stress components in real blood contacting devices.

Experimental measurement and numerical modelling of dye washout for investigation of blood residence time in ventricular assist devices

Ventricular assist devices have become the standard therapy for end-stage heart failure. However, their use is still associated with severe adverse events related to the damage done to the blood by fluid dynamic stresses. This damage relates to both the stress magnitude and the length of time the blood is exposed to that stress. We created a dye washout technique which combines experimental and numerical approaches to measure the washout times of ventricular assist devices. The technique was used to investigate washout characteristics of three commercially available and clinically used ventricular assist devices: the CentriMag, HVAD and HeartMate II. The time taken to reach 5% dye concentration at the outlet (T05) was used as an indicator of the total residence time. At a typical level of cardiac support, 5 L/min and 100 mmHg, T05 was 0.93, 0.28 and 0.16 s for CentriMag, HVAD and HeartMate II, respectively, and increased to 5.06, 1.64 and 0.96 s for reduced cardiac support of 1 L/min. Regional variations in washout characteristics are described in this article. While the volume of the flow domain plays a large role in the differences in T05 between the ventricular assist devices, after standardising for ventricular assist device volume, the secondary flow path was found to increase T05 by 35%. The results explain quantitatively, for the first time, why the CentriMag, which exerts low shear stress magnitude, has still been found to cause acquired von Willebrand Syndrome in patients.